Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eledon Pharmaceuticals, Inc. (ELDN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated Aggregate mean eGFR was above 70 mL/min/1.73m 2 at all reported time points after day 90 supporting tegoprubart's potential to protect organ function in patients undergoing kidney transplantation Eledon will host a conference call today at 5:00 p.m. ET IRVINE, Calif.

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D.

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

IRVINE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company will present a poster at the American Society of Nephrology's upcoming Kidney Week 2023 Annual Meeting taking place in Philadelphia, PA from November 2-5, 2023.

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Allan Douglas Kirk, M.D.

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Landmark cardiac xenotransplantation procedure conducted at University of Maryland Medical Center Tegoprubart, administered investigationally to prevent organ rejection post-transplant, targets the CD40L pathway known to play an essential role in both innate and adaptive immune cell activation and function. IRVINE, Calif.

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

IRVINE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a panel presentation at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023, at 8:00 a.m. ET.

Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

IRVINE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as Chief Executive Officer and Director of Urovant Sciences until its merger with Sumitomo Pharma America on July 1, 2023.

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

Trial to assess potential of tegoprubart-based immunosuppression to improve graft function compared to tacrolimus-based immunosuppression Trial to assess potential of tegoprubart-based immunosuppression to improve graft function compared to tacrolimus-based immunosuppression

Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation; updated clinical data expected in the fourth quarter

Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results

IRVINE, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.

Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Paul Little - Chief Financial Officer David-Alexandre Gros - Chief Executive Officer Steve Perrin - President and Chief Scientific Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Thomas Smith - SVB Securities Rami Katkhuda - LifeSci Capital Vernon Bernardino - H.C. Wainwright Raymond Wu - Ladenburg Thalmann Operator Good afternoon, ladies and gentlemen and welcome to Eledon Pharmaceuticals first quarter 2023 earnings conference call.

Eledon Pharmaceuticals, Inc. (ELDN) Q1 2023 Earnings Call Transcript

Tegoprubart has the potential to become the first-line immunomodulatory agent after kidney transplantation, a $375M/year U.S. revenue opportunity. The company has a negative enterprise value, so investors are ignoring the pipeline despite promising early clinical data.

Eledon Pharmaceuticals: Disrupting The Kidney Transplantation Landscape

Results from three participants demonstrated no incidence of acute rejection at durations of 56, 154, and 232 days

Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Paul Little - Chief Financial Officer David-Alexandre Gros - Chief Executive Officer Steven Perrin - President and Chief Scientific Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Thomas Smith - SVB Leerink Securities Matt Kaplan - Ladenburg Thalmann Rami Katkhuda - LifeSci Capital Operator Greetings, and welcome to the Eledon Pharmaceuticals Fourth Quarter and Full-Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Eledon Pharmaceuticals, Inc. (ELDN) Q4 2022 Earnings Call Transcript

`Four patients enrolled in open-label Phase 1b kidney transplant trial with clinical data on first three patients to be presented at the World Congress of Nephrology (WCN) on March 31, 2023

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results

Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023

IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the upcoming SVB Securities Global Biopharma Conference on February 15, 2023, at 5:00 p.m. ET.

Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

Company plans to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation

Eledon Pharmaceuticals Provides Business and Pipeline Updates

Eledon to Incorporate the iBox Scoring System in Future Kidney Transplant Trials Eledon to Incorporate the iBox Scoring System in Future Kidney Transplant Trials

C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Paul Little – Chief Financial Officer David-Alexandre Gros – Chief Executive Officer Steve Perrin – President and Chief Scientific Officer Jeff Bornstein – Chief Medical Officer Conference Call Participants Pete Stavropoulos – Cantor Fitzgerald Matt Kaplan – Ladenburg Thalmann Thomas Smith – SVB Securities Rami Katkhuda – LifeSci Capital Operator Good day and welcome to the Eledon Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode.

Eledon Pharmaceuticals, Inc. (ELDN) Q3 2022 Earnings Call Transcript

Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant

Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society of Nephrology's (ASN) Kidney Week 2022 being held November 3-6, 2022, in Orlando, Florida. The Company will also present one poster at the upcoming Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) which is being held November 1-3, 2022, in Clearwater Beach, Florida.

News for Eledon Pharmaceuticals Stock (ELDN)